CD70 and nonpapillary renal cell carcinoma: To overcome antigenic heterogeneity, dual-targeted fine-tuned immune-restoring (DFIR) CAR-T for ccRCC, targeting CAIX and CD70, and engineered for concurrent secretion of ICI is also undergoing pre-clinical testing [84].